1887
  1. Home
  2. A-Z Publications
  3. Qatar Journal of Public Health
  4. Volume 2023, Issue 2
  5. Article
Volume 2023, Issue 2
  • EISSN:

Abstract

التَّصلُّب الجانبي الضُّموري هو أحد الأمْراض العَصَبيَّة التَنَكُّسِيَّة التي تُصيب الخلايا العَصَبيَّة في المُخ والحَبْلِ الشَّوكِي، ويَنْتَهي المرض غَالباً بالوفاةِ. هَدَفَت هذه الدراسة لتَلخيص خَصَائِص مَرْضَى التَّصلٌّب الجانبي الضُّموري في البُلدان العَرَبية ومَدى جَودة الرِعاية الصحِّيَّة المُقدَّمة لهم.

تَمَّ إجْراء هذه الدِّراسة وِفْقَاً للمبادِئ التَّوجِيهيَّة للمُراجعات المَنْهَجِيَّة والتَّحالِيل التلوية (PRISMA). تَمَّ إجراء بحث مُحَوْسَب في ثلاث قواعد بيانات في الأول من شَهر كَانُون الْأَوَّل لعام 2023م باستخدام المصطلحات المناسبة. تَضَمَّنَت مَعايير الأَهْلية أن تكون الدِراسة أوَّلية وَصفيَّة للتَركِيبة الدِّيمُوغْرافية أو الخَصَائص السَّريرية أو الرِعَاية الصحِّيَّة لمرضى التَّصلُّب الجانبي الضُّموري في أي من البُلدان العَرَبيَّة. تَمَّ إنشاء التَّحليل التلوي والرسومات البيَّانِية الغَابيَّة باستِخدام بِرنامج R Studio وذلك باستخدام نَمُوذَج تَحليل التأثير العشوائي. تمَّ حِساب النِّسبَة المئويَّة للمُتغيرات الفِئويَّة والمُتوسِّط الكُلي للمُتغيرات المُستمرة مع فَاصِل الثِّقة 95% لتقدير الحجم الشُّمولي.

بَعد فَحص الأدبيات، تَمَّ تَحدِيد وإدراج سبع دِراسات - جيدة الجَودة - مُوافِقة لمعايير الأهليَّة. شَملت هذه الدراسات خَمس دراسات وَصْفِيَّة لمَرضَى التَّصلُّب الجَانِبي الضُّموري ودراسَتين تَمَّ إجراؤهم عَلى مُقدِّمِي الرِعَاية الصحِّيَّة. أَظهَرَ التَّحليل التلوي أنَّ نِسبَة الذُكور الشُّموليَّة عَبرَ كَافة الدراسات 63% مع فَاصِل ثِقَة يَتَرَاوح بين 57% و69%. كانت نِسبَة المُصابين بالنٌوع البَصَلِي للمَرَض عَبرَ كَافة الدِراسات 23% مع فاصل ثقة يتراوح بين 19% و28%. كما كَانَ المُتَوَسط الشُّمولي لعُمر المَرضَى عِندَ بِداية المَرض 53.3 سنة مع فاصل ثقة يتراوح بين 51.6 و55.1 سنة. أَشَارَت الدِراستان الخاصتان بِالرِّعَايَة الصحِّيَّة إلى ضَعْف كَفَاءَة الرِعَاية الطِّبيَّة بِمَرضَى التَّصلُّب الجانبي الضُّموري.

تُشير هَذِه المُراجَعة إلى نُدرة وقِلَّة الأدَبِيَّات البَحثيَّة المَنشُورَة عَن مَرضَى التَّصلُّب الجَانِبي الضُّموري فِي البُلدان العَرَبيَّة. فِيمَا يَخص الأدبيات المُتاحَة فإِنها تُشير إلى أنَّه فِي حِين أنَّ مَرضَى التَّصلُّب الجَانِبي الضُّموري يَتَشَارَكُون بَعض السِمَات السُكَّانِيَّة والسَريريَّة مَعَ المَرضَى مِن مَناطِق أُخرى، إلَّا أنَّ هُناك اختلافات ملحوظة، كما أَشَارَت الدِراسَات أيضاً إلى ضَعف كَفَاءَة الرّعاية الصحِّيَّة المُقَدَّمَة. يُوْصَى بِتَوجيه المَزيد مِن الأبحاث لدِراسَة مَرضَى التَّصلُّب الجَانِبِي الضُّمُورِي فِي العَالَم العَرَبِي.

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects upper and lower motor neurons and is ultimately fatal. This study aimed to investigate ALS patients’ demographics, clinical features, and healthcare situation in Arab countries.

Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a literature search was conducted on 1st December 2023 using appropriate search terms in three databases. Inclusion criteria encompassed observational studies that reported on the demographics, clinical features, or healthcare of ALS patients in any Arab country. The meta-analysis and the forest plots were generated by R Studio using the DerSimonian Laird random effect meta-analysis model.

Seven studies met the inclusion criteria and were included in the review. Among these, five were observational studies focusing on ALS patients, while two examined the healthcare provided to ALS patients. The pooled proportion of males across all studies was 63% (95% CI = 57% to 69%). Meanwhile, the pooled proportion of patients with bulbar ALS was 23% (95% CI = 91% to 28%). The overall mean age of patients at the onset of the disease was 53.3 years (95% CI = 51.6 to 55.1). The two healthcare studies reported subpar health and medical care for ALS patients.

This systematic review highlights the limited literature on ALS in Arab countries. The findings suggest that while Arab ALS patients share some demographic and clinical features with patients from other regions, there are also notable differences. Further research is needed to enhance our understanding of ALS in Arab countries and improve healthcare provisions for affected individuals.

© 2023 [Author(s)], licensee HBKU Press.
Loading

Article metrics loading...

/content/journals/10.5339/qjph.2023.10
2024-01-31
2024-05-16
Loading full text...

Full text loading...

/deliver/fulltext/qjph/2023/2/qjph.2023.10.html?itemId=/content/journals/10.5339/qjph.2023.10&mimeType=html&fmt=ahah

References

  1. van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, et al. Amyotrophic lateral sclerosis. Lancet. 2017; 390:(10107):2084–98. doi: 10.1016/S0140-6736(17)31287-4.
     [Google Scholar]
  2. Brown CA, Lally C, Kupelian V, Flanders WD. Estimated Prevalence and Incidence of Amyotrophic Lateral Sclerosis and SOD1 and C9orf72 Genetic Variants. Neuroepidemiology. 2021 55:(5):342–53. doi: 10.1159/000516752.
     [Google Scholar]
  3. Sanjak M, Langford V, Holsten S, Rozario N, Patterson CGM, Bravver E, et al. Six-Minute Walk Test as a Measure of Walking Capacity in Ambulatory Individuals With Amyotrophic Lateral Sclerosis. Arch Phys Med Rehabil. 2017 98:(11):2301–7. doi: 10.1016/j.apmr.2017.04.004.
     [Google Scholar]
  4. Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Prim. 2017;3:17071. doi: 10.1038/nrdp.2017.71.
     [Google Scholar]
  5. Sanjak M, Brinkmann J, Belden D., Roelke K, Waclawik A, Neville H., et al. Quantitative assessment of motor fatigue in amyotrophic lateral sclerosis. J Neurol Sci. 2001; 191:(1-2):55–9. doi: 10.1016/S0022-510X(01)00624-4.
     [Google Scholar]
  6. Hurwitz N, Radakovic R, Boyce E, Peryer G. Prevalence of pain in amyotrophic lateral sclerosis: a systematic review and meta-analysis. Amyotroph Lateral Scler Front Degener. 2021; 22:(7-8):449–58. doi: 10.1080/21678421.2021.1892765.
     [Google Scholar]
  7. Heidari ME, Nadali J, Parouhan A, Azarafraz M, tabatabai SM, Irvani SSN, et al. Prevalence of depression among amyotrophic lateral sclerosis (ALS) patients: A systematic review and meta-analysis. J Affect Disord. 2021;287:182–90. doi: 10.1016/j.jad.2021.03.015.
     [Google Scholar]
  8. Hamad AA, Amer BE, Abbas NB, Alnajjar AZ, Meshref M. Prevalence and correlates of fatigue in amyotrophic lateral sclerosis: A systematic review and meta-analysis. Neurol Sci. 2023. doi: 10.1007/s10072-023-07119-7.
     [Google Scholar]
  9. Simmons Z. Management Strategies for Patients With Amyotrophic Lateral Sclerosis From Diagnosis Through Death. Neurologist. 2005 11:(5):257–70. doi: 10.1097/01.nrl.0000178758.30374.34.
     [Google Scholar]
  10. Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, et al. Practice Parameter update: The care of the patient with amyotrophic lateral sclerosis: Drug, nutritional, and respiratory therapies (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009 73:(15):1218–26. doi: 10.1212/WNL.0b013e3181bc0141.
     [Google Scholar]
  11. Stenson K, O’Callaghan L, Mellor J, Wright J, Gibson G, Earl L, et al. Healthcare resource utilization at different stages of amyotrophic lateral sclerosis: Results from a real-world survey. J Neurol Sci1. 2023;452:120764. doi: 10.1016/j.jns.2023.120764.
     [Google Scholar]
  12. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994 330:(9):585–91. doi: 10.1056/NEJM199403033300901.
     [Google Scholar]
  13. Nourelden AZ, Kamal I, Hagrass AI, Tawfik AG, Elhady MM, Fathallah AH, et al. Safety and efficacy of edaravone in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis. Neurol Sci. 2023 44:(10):3429–42. doi: 10.1007/s10072-023-06869-8.
     [Google Scholar]
  14. Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott MA, Maiser S, et al. Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis.N Engl J Med. 2020 383:(10):919–30. doi: 10.1056/NEJMoa1916945.
     [Google Scholar]
  15. Koeman T, Slottje P, Schouten LJ, Peters S, Huss A, Veldink JH, et al. Occupational exposure and amyotrophic lateral sclerosis in a prospective cohort. Occup Environ Med. 2017 74:(8):578–85. doi: 10.1136/oemed-2016-103780.
     [Google Scholar]
  16. Page MJ, Mckenzie JE, Bossuyt PM, Boutron I, Hoffmann C, Mulrow CD, et al. The PRISMA 2020 statement : an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.
     [Google Scholar]
  17. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5:210. doi: 10.1186/s13643-016-0384-4.
     [Google Scholar]
  18. Hamad AA. Reconsidering the Need for De-Duplication Prior to Screening in Systematic Reviews. AlQ J Med Appl Sci. 2023 6:(2):367–8. doi: 10.5281/zenodo.8126972.
     [Google Scholar]
  19. Ma L-L, Wang Y-Y, Yang Z-H, Huang D, Weng H, Zeng X-T. Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better? Mil Med Res. 2020;7:7. doi: 10.1186/s40779-020-00238-8.
     [Google Scholar]
  20. Luna J, Diagana M, Ait Aissa L, Tazir M, Ali Pacha L, Kacem I, et al. Clinical features and prognosis of amyotrophic lateral sclerosis in Africa: the TROPALS study. J Neurol Neurosurg Psychiatry. 2019 90:(1):20–9. doi: 10.1136/jnnp-2018-318469.
     [Google Scholar]
  21. Luna J, Jost J, Diagana M, Ait Aissa L, Tazir M, Ali Pacha L, et al. Clinical management and disease-modifying treatment for amyotrophic lateral sclerosis in African hospital centers: the TROPALS study. Amyotroph Lateral Scler Frontotemporal Degener. 2022 May;23(3-4):279-283. doi: 10.1080/21678421.2021.1961806.
     [Google Scholar]
  22. Abuzinadah AR, AlShareef AA, AlKutbi A, Bamaga AK, Alshehri A, Algahtani H, et al. Amyotrophic lateral sclerosis care in Saudi Arabia: A survey of providers’ perceptions. Brain Behav. 2020 10:(10):e01795. doi: 10.1002/brb3.1795.
     [Google Scholar]
  23. Drory VE, Artmonov I. Earlier onset and shorter survival of amyotrophic lateral sclerosis in Jewish patients of North African origin. J Neurol Sci. 2007; 258:(1-2):39–43. doi: 10.1016/j.jns.2007.02.021.
     [Google Scholar]
  24. Imounan F, Lahbouje S, Hsaini Y, Regragui W, Ait Ben Haddou el H, Benomar A, et al. Aspects cliniques et environnementaux de la sclérose latérale amyotrophique chez une population morocaine: etude de 60 cas [Clinical and environmental aspects of amyotrophic lateral sclerosis in moroccan population: a study of 60 cases]. Tunis Med. 2015 Jun; 93:(6):365-70. French.
     [Google Scholar]
  25. Kacem I, Sghaier I, Bougatef S, Nasri A, Gargouri A, Ajroud-Driss S, et al. Epidemiological and clinical features of amyotrophic lateral sclerosis in a Tunisian cohort. Amyotroph Lateral Scler Frontotemporal Degener. 2020; 21:(1-2):131–9. doi: 10.1080/21678421.2019.1704012.
     [Google Scholar]
  26. Malek E, Ismail H, Doumiati H, Salameh J. Characteristics of amyotrophic lateral sclerosis in Lebanon-a chart review. Amyotroph Lateral Scler Frontotemporal Degener. 2020 Nov; 21:(7-8):614-619. doi: http://dx.doi.org/10.1080/21678421.2020.1788095.
     [Google Scholar]
  27. Mehta P, Raymond J, Punjani R, Larson T, Bove F, Kaye W, et al. Prevalence of amyotrophic lateral sclerosis (ALS), United States, 2016. Amyotroph Lateral Scler Frontotemporal Degener. 2022 May; 23:(3-4):220-225. doi: 10.1080/21678421.2021.
     [Google Scholar]
  28. Ragonese P, Cellura E, Aridon P, D’amelio M, Spataro R, Taiello AC, et al. Incidence of amyotrophic lateral sclerosis in Sicily: A population based study. Amyotroph Lateral Scler. 2012 13:(3):284–7. doi: 10.3109/17482968.2012.662689.
     [Google Scholar]
  29. Pradas J, Puig T, Rojas-García R, Viguera ML, Gich I, Logroscino G, et al. Amyotrophic lateral sclerosis in Catalonia: A population based study. Amyotroph Lateral Scler Frontotemporal Degener. 2013 May; 14:(4):278-83. doi: 10.3109/21678421.2012.749915.
     [Google Scholar]
  30. Scialò C, Novi G, Bandettini di Poggio M, Canosa A, Sormani MP, Mandich P, et al. Clinical epidemiology of amyotrophic lateral sclerosis in Liguria, Italy: An update of LIGALS register. Amyotroph Lateral Scler Frontotemporal Degener. 2016 Oct-Nov; 17:(7-8):535-542. doi: 10.1080/21678421.2016.1197942.
     [Google Scholar]
  31. Rashed HR, Tork MA. Diagnostic dilemma of amyotrophic lateral sclerosis (ALS): insights from the first ALS specialized clinic in Egypt. Egypt J Neurol Psychiatry Neurosurg. 2020;56:69. doi: 10.1186/s41983-020-00203-1.
     [Google Scholar]
  32. Kacem I, Sghaier I, Peverelli S, Souissi E, Ticozzi N, Gharbi A, et al. Genotype-phenotype correlation in Tunisian patients with Amyotrophic Lateral Sclerosis. Neurobiol Aging. 2022;120:27–33. doi: 10.1016/j.neurobiolaging.2022.08.002.
     [Google Scholar]
  33. Rekik A, Mrabet S, Kacem I, Nasri A, Ben Djebara M, Gargouri A, et al. Eye Movement Abnormalities in Amyotrophic Lateral Sclerosis in a Tunisian Cohort. Neuroophthalmology. 2022 Mar 2; 46:(4):227-235. doi: 10.1080/01658107.2022.2038638.
     [Google Scholar]
  34. Soliman R, Mousa NO, Rashed HR, Moustafa RR, Hamdi N, Osman A, et al. Assessment of diagnostic potential of some circulating microRNAs in Amyotrophic Lateral Sclerosis Patients, an Egyptian study. Clin Neurol Neurosurg. 2021;208:106883. doi: 10.1016/j.clineuro.2021.106883.
     [Google Scholar]
  35. Rashed HR, Tork MA, Soliman R, Serag R, Fahmy N. Arabic adaptation and validation of the revised amyotrophic lateral sclerosis functional rating scale (ALSFRS-R): Egyptian study. Amyotroph Lateral Scler Frontotemporal Degener. 2021 May; 22:(3-4):220-222. doi: 10.1080/21678421.2020.1815788.
     [Google Scholar]
  36. Soliman R, Rashed HR, Moustafa RR, Hamdi N, Swelam MS, Osman A, et al. Egyptian adaptation and validation of the Edinburgh Cognitive and Behavioral Amyotrophic Lateral Sclerosis Screen (ECAS-EG). Neurol Sci. 2023 44:(6):1871–80. doi: 10.1007/s10072-023-06639-6.
     [Google Scholar]
  37. Kacem I, Abida Y, Ferchichi W, Mrabet S, Sghaier I, Gharbi A, et al. Arabic adaptation of the Edinburgh cognitive and behavioural Amyotrophic lateral sclerosis screen (ECAS-AR). Rev Neurol (Paris). 2022 178:(8):817–25. doi: 10.1016/j.neurol.2021.12.015.
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/qjph.2023.10
Loading
التَّركِيبَة السُكَّانِيَّة والخَصَائِص السَّريرِيَّة وجَودة الرِعَايَة الصحِّيَّة لمَرضَى التَّصلُّب الجَانِبي الضُّموري في البُلدانِ العَرَبِيّة: مُراجعة مَنْهَجِيَّة وتَحليل تَلوي
QJPH 2023, 10 (2024); https://doi.org/10.5339/qjph.2023.10
/content/journals/10.5339/qjph.2023.10
/content/journals/10.5339/qjph.2023.10
Loading

Data & Media loading...

  • Article Type: Research Article
Keyword(s): Amyotrophic lateral sclerosis, Arab, ALS and التٰصلّب الجانبي الضّموري، البُلدان العَرَبيٰة، العَالَم العَرَبِي
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error